Chemistry42
A generative AI platform for small molecule drug discovery, streamlining hit identification to lead optimization.
Executive Summary
Chemistry42 is a generative chemistry engine developed by Insilico Medicine for de novo molecular design. Launched in 2020, it is a customizable and fully automated software platform that integrates generative AI algorithms with computational and medicinal chemistry approaches. The platform is designed to streamline the entire small molecule drug discovery process, from hit identification and hit-to-lead to lead optimization programs. It utilizes a multi-model AI system, including an ensemble of generative and scoring engines, to automatically create drug-like molecular structures with appropriate physicochemical properties. This capability has been instrumental in designing drug candidates that have progressed to clinical trials, demonstrating its effectiveness in accelerating pharmaceutical research and development.
Use Cases
- De novo molecular design for novel compounds
- Hit identification in early-stage drug discovery
- Hit-to-lead optimization programs
- Lead optimization for improved drug candidates
- Designing drug candidates for clinical trials
Features
Visibility
- Molecular Structure Visualization: Interactive visualization of generated molecular structures and their associated properties.
- Case Study Exploration: Ability to explore and analyze results from Insilico's internal case studies run with Chemistry42.
Intelligence
- De Novo Molecular Design: Generates novel small molecule structures from scratch based on specified parameters and constraints.
- Multi-Model Generative AI: Utilizes an ensemble of generative AI models to explore chemical space and propose diverse drug candidates.
- Property Prediction & Scoring: Predicts and scores physicochemical properties and drug-likeness of generated molecules to guide optimization.
Technical Specifications
- Architecture
- An ensemble of generative AI and scoring engines, integrated into a customizable and automated software platform for small molecule drug discovery.
- Deployment
- SaaS
AI/ML Stack
- Generative AI
- Machine Learning
- Deep Learning
Pricing
- Starting Price
- Contact sales
- Target Customer
- Enterprise,Mid-Market
About Insilico Medicine
Insilico Medicine is a clinical-stage biotechnology company that leverages artificial intelligence and deep learning to accelerate drug discovery and development. The company focuses on therapeutic solutions for cancer, fibrosis, immunity, central nervous system diseases, and age-related conditions, utilizing its proprietary Pharma.AI platform to discover novel targets, design new molecules, and advance candidates into human clinical trials.
Alternatives to Chemistry42
- ChemML Discovery Platform by Insitro — Accelerating drug discovery through chemistry machine learning and strategic collaborations.
- Cortellis by Clarivate — Equip your R&D ecosystem with intelligence to make confident, speedy decisions across drug and device development.
- Cyprotex by Evotec — Predictive ADME-Tox solutions for enhanced drug safety and success.
- DORA by Insilico Medicine — AI-driven tool to streamline academic paper drafting and accelerate drug discovery research.
- DRG Fusion by Clarivate — Ignite commercial success in life sciences and healthcare with modular analytics powered by real-world data.
- Drug Creation Partnerships by Absci — Leverage Absci's AI and wet lab platform for rapid discovery of breakthrough biologics.
- Drug Discovery & Pre-clinical Development Services by Evotec — Integrated R&D programs and standalone services for accelerated drug discovery and preclinical development.
- EVA Platform by LabGenius — AI-driven platform for ultra-high-throughput protein engineering and antibody discovery.